Directory of Pharma Companies and News

Company Profile


Imcyse logo
Imcyse develops active targeted immunotherapies to treat and prevent severe chronic diseases caused by disruptions of the immune system. The company’s unique active immunotherapy technology platform allows to locally destroying the immune cells involved in the destruction of the diseased organ. This platform is based on the administration of Imotopes™, which are specific modified peptides, allowing for the generation of a new type of T-cells, called cytolytic CD4 T cells. The effects of the Imcyse approach that are sustained overtime help to prevent and treat diseases with no current therapeutic alternative and to cure the patient without impairing its immune defenses. The company has established proof of concept and is launching its first clinical trial in type 1 diabetes, in five European countries.

Other projects, which address multiple sclerosis and rheumatoid arthritis, are at preclinical and proof-of-concept research stages, respectively. Founded in 2010, Imcyse is a spin-off from the Katholieke Universiteit Leuven (KUL), Belgium. The company is based near the Belgian city of Liège. It is managed by a small group of pharmaceutical industry experts. Imcyse has already raised a total of €20 million from private and public investors.

0 results
Brought to you by - Latest Jobs in Pharma